CUV 0.87% $13.61 clinuvel pharmaceuticals limited

who can afford afamelanotide?

  1. 648 Posts.
    I have never seen from any source just how even those in need of afamelanotide (the target patient population) will pay for this.

    If we assume the analyst's 1500 euro price point per implant, who but the well-to-do could afford this?

    As an investor, I need to know whether there will be some sort of government reimbursement for these patients. Because I there are many people even in developed economies who cannot afford a 1500 euro drug (assuming the analyst is in ballpark range with his estimates of the price point).

    The analyst projects 5 implants per year at a annual cost of 7500 euros.

    I hear people bellyaching about drugs that cost $100 per month.

    So, just how will people pay for a 1500 euro drug? Do you get out a loan? Mortgage your house? Sell your 2nd car? Sell your plasma?

    I'm being serious here. All the talk of the market population will need to explain what the plan is to allow these EPP sufferers to pay for this.

    A few years ago, an analyst report projected a per implant price of $300. So if the drug is going to be multiples of that, how about some explanation to shareholders just how the target population will be able to afford it? Seems reasonable to me.

    1500 euros is expensive. I bounced this off some who said the price is outrageous. Yes, I know it's a orphan status drug.

    But, that doesn't take away the fact that if the drug is going to be 1500 euros, IMO it is outrageously high priced and could raise some ethical issues.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$13.61
Change
-0.120(0.87%)
Mkt cap ! $681.3M
Open High Low Value Volume
$13.71 $14.12 $13.55 $802.2K 58.69K

Buyers (Bids)

No. Vol. Price($)
1 2300 $13.60
 

Sellers (Offers)

Price($) Vol. No.
$13.73 241 1
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.